• 1
    Fermi C, Pernosi L. Untersuchungen uber die enzyme. Veigerchende Studie Z Hig Infectionskr 1894; 18: 839.
  • 2
    Schultze HE, Goilner I, Heide K, Schoenenberger M, Schwick G. Zur Kenntnis der alpha-globulin des menschlichen nirmal serums. Z Naturforsch 1995; 10: 463.
  • 3
    Laurell CB, Eriksson S. The electrophoretic alpha1-globulin pattern of serum in alpha1-antitrypsin deficiency. Scand J Clin Lab Invest 1963; 15: 13240.
  • 4
    Eriksson S. Pulmonary emphysema and alpha-l-antitrypsin deficiency. Acta Med Scand 1964; 175: 197205.
  • 5
    Laurell CB, Eriksson S. The serum alpha-l-antitrypsin in families with hypo-alpha-l-antitrypsinemia. Clin Chim Acta 1965; 11: 3958.
  • 6
    Fagerhol MK, Laurell CB. The polymorphism of “prealbumins” and alpha-1-antitrypsin in human sera. Clin Chim Acta 1967; 16: 199203.
  • 7
    Fagerhol MK. The Pi-system, genetic variants of serum 1 antitrypsin. Ser Haematol 1968; 151: 15361.
  • 8
    Sharp HL, Bridges RA, Krivit W, Freier EF. Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder. J Lab Clin Med 1969; 73: 9349.
  • 9
    Turino GM, Senior RM, Garg BD, Keller S, Levi MM, Mandl I. Serum elastase inhibitor deficiency and alpha 1-antitrypsin deficiency in patients with obstructive emphysema. Science 1969; 165: 70911.
  • 10
    Janoff A, Scherer J. Mediators of inflammation in leukocyte lysosomes. IX. Elastinolytic activity in granules of human polymorphonuclear leukocytes. J Exp Med 1968; 128: 113755.
  • 11
    Berg NO, Eriksson S. Liver disease in adults with alpha-1 -antitrypsin deficiency. N Engl J Med 1972; 287: 12647.
  • 12
    Allen RC, Harley RA, Talamo RC. A new method for determination of alpha-1-antitrypsin phenotypes using isoelectric focusing on polyacrylamide gel slabs. Am J Clin Pathol 1974; 62: 7329.
  • 13
    Owen MC, Carrell RW, Brennan SO. The abnormality of the S variant of human alpha-1-antitrypsin. Biochim Biophys Acta 1976; 453: 25761.
  • 14
    Pierce J, Jeppsson J-O, Laurell C-B. alpha-Antitrypsin phenotypes determined by isoelectric focusing of the cysteine antitrypsin mixed disulfide in serum. Anal Biochem 1976; 74: 22741.
  • 15
    Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976; 294: 131621.
  • 16
    Sveger T, Eriksson S. The liver in adolescents with alpha 1-antitrypsin deficiency. Hepatology 1995; 22: 5147.
  • 17
    Bernspång E, Wollmer P, Sveger T, Piitulainen E. Lung function in 30-year-old alpha-1-antitrypsin-deficient individuals. Respir Med 2009; 103: 8615.
  • 18
    Larsson C, Eriksson S, Dirksen H. Smoking and intermediate alpha1-antitrypsin deficiency and lung function in middle-aged men. Br Med J 1977; 2: 9225.
  • 19
    Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand 1978; 204: 34551.
  • 20
    Cox DW. Genetic variation in alpha-1-antitrypsin. Am J Hum Genet 1978; 30: 6602.
  • 21
    Cox DW, Johnson AM, Fagerhol MK. Report of nomenclature meeting for alpha 1-antitrypsin, INSERM, Rouen/Bois-Guillaume-1978. Hum Genet 1980; 53: 42933.
  • 22
    Long GL, Chandra T, Woo SL, Davie EW, Kurachi K. Complete sequence of the cDNA for human alpha 1-antitrypsin and the gene for the S variant. Biochemistry 1984; 23: 482837.
  • 23
    Perlino E, Cortese R, Ciliberto G. The human alpha 1-antitrypsin gene is transcribed from two different promoters in macrophages and hepatocytes. EMBO J 1987; 6: 276771.
  • 24
    Gadek JE, Klein HG, Holland PV, Crystal RG. Replacement therapy of alpha 1-antitrypsin deficiency. Reversal of protease-antiprotease imbalance within the alveolar structures of PiZ subjects. J Clin Invest 1981; 68: 115865.
  • 25
    From the NIH: intravenous replacement therapy for patients with severe alpha 1-antitrypsin deficiency. JAMA 1982; 248: 1693.
  • 26
    Wewers MD, Casolaro MA, Sellers SE et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316: 105562.
  • 27
    Hubbard RC, Sellers S, Czerski D, Stephens L, Crystal RG. Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA 1988; 260: 125964.
  • 28
    American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168: 818900.
  • 29
    Bornhorst JA, Greene DN, Ashwood ER, Grenache DG. α1-Antitrypsin phenotypes and associated serum protein concentrations in a large clinical population. Chest 2013; 143: 10008.
  • 30
    Lee JH, Brantly M. Molecular mechanisms of alpha1-antitrypsin null alleles. Respir Med 2000; 94(Suppl C): S711.
  • 31
    Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365: 222536.
  • 32
    Stoller JK, Aboussouan LS. A review of α1-antitrypsin deficiency. Am J Respir Crit Care Med 2012; 185: 24659.
  • 33
    Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992; 357: 6057.
  • 34
    Ekeowa UI, Freeke J, Miranda E et al. Defining the mechanism of polymerization in the serpinopathies. Proc Natl Acad Sci U S A 2010; 107: 1714651.
  • 35
    Turino GM, Barker AF, Brantly ML et al. Clinical features of individuals with PI*SZ phenotype of alpha 1-antitrypsin deficiency. alpha 1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1996; 154: 171825.
  • 36
    McElvaney NG, Stoller JK, Buist AS et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest 1997; 111: 394403.
  • 37
    Walsh JW, Snider GL, Stoller JK. A review of the alpha-1 foundation: its formation, impact, and critical success factors. Respir Care 2006; 51: 52631.
  • 38
    Walsh JW. How patients learned to control their own future. COPD 2013; 10: 579.
  • 39
    Stockley RA, Luisetti M, Miravitlles M, Piitulainen E, Fernandez P, Alpha One International Registry (AIR) group. Ongoing research in Europe: Alpha One International Registry (AIR) objectives and development. Eur Respir J 2007; 29: 5826.
  • 40
    Stockley RA, Dirksen A, Stolk J. Alpha-1 antitrypsin deficiency: the European experience. COPD 2013; 10(Suppl 1): 503.
  • 41
    Lara B, de la Roza C, Vilà S, Vidal R, Miravitlles M. Development and results of the Spanish registry of patients with alpha-1-antitrypsin deficiency. Int J Chron Obstruct Pulmon Dis 2007; 2: 3938.
  • 42
    Hutchison DC. Alpha 1-antitrypsin deficiency in Europe: geographical distribution of Pi types S and Z. Respir Med 1998; 92: 36777.
  • 43
    Luisetti M, Seersholm N. Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency. Thorax 2004; 59: 1649.
  • 44
    de Serres FJ. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002; 122: 181829.
  • 45
    Blanco I, de Serres FJ, Fernandez-Bustillo E, Lara B, Miravitlles M. Estimated numbers and prevalence of PI*S and PI*Z alleles of alpha1-antitrypsin deficiency in European countries. Eur Respir J 2006; 27: 7784.
  • 46
    Blanco I, de Serres FJ, Cárcaba V, Lara B, Fernández-Bustillo E. Alpha-1 antitrypsin deficiency PI*Z and PI*S gene frequency distribution using on maps of the world by an inverse distance weighting (IDW) multivariate interpolation method. Hepat Mon 2012; 12(10 HCC): e7434.
  • 47
    de Serres FJ, Blanco I. Prevalence of α1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Ther Adv Respir Dis 2012; 6: 27795.
  • 48
    de Serres FJ, Luisetti M, Ferrarotti I, Blanco I, Fernández-Bustillo E. Alpha-1 antitrypsin deficiency in Italy: regional differences of the PIS and PIZ deficiency alleles. Monaldi Arch Chest Dis 2005; 63: 13341.
  • 49
    de Serres FJ, Blanco I, Bustillo EF. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: evidence supporting targeted screening, COPD: J of. COPD 2006; 3: 1339.
  • 50
    de Serres FJ, Blanco I, Bustillo EF. Ethnic differences in alpha-1 antitrypsin deficiency in the United States of America. Ther Adv Respir Dis 2010; 4: 6370.
  • 51
    Alam S, Li Z, Janciauskiene S, Mahadeva R. Oxidation of Z alpha1-antitrypsin by cigarette smoke induces polymerization: a novel mechanism of early-onset emphysema. Am J Respir Cell Mol Biol 2011; 45: 2619.
  • 52
    Mahadeva R, Atkinson C, Li Z et al. Polymers of Z alpha1-antitrypsin co-localize with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 2005; 166: 37786.
  • 53
    Petrache I, Fijalkowska I, Medler TR et al. alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol 2006; 169: 115566.
  • 54
    Brantly M. α1-antitrypsin: not just an antiprotease. Extending the half-life of a natural anti-inflammatory molecule by conjugation with polyethylene glycol. Am J Respir Cell Mol Biol 2002; 27: 6524.
  • 55
    Holmes M, Curiel D, Brantly M, Crystal RG. Characterization of the intracellular mechanism causing the alpha-1-antitrypsin Nullgranite falls deficiency state. Am Rev Respir Dis 1989; 140: 16627.
  • 56
    Janciauskiene SM, Bals R, Koczulla R, Vogelmeier C, Köhnlein T, Welte T. The discovery of α1-antitrypsin and its role in health and disease. Respir Med 2011; 105: 112939.
  • 57
    Janciauskiene S. Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles. Biochim Biophys Acta 2001; 1535: 22135.
  • 58
    Pott GB, Chan ED, Dinarello CA, Shapiro L. Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol 2009; 85: 88695.
  • 59
    Bergin DA, Reeves EP, Meleady P et al. α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest 2010; 120: 423650.
  • 60
    Blanco I, Lara B, de Serres F. Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema. Orphanet J Rare Dis 2011; 6: 14.
  • 61
    Lewis EC. Expanding the clinical indications for α(1)-antitrypsin therapy. Mol Med 2012; 18: 95770.
  • 62
    Wanner A, Arce AD, Pardee E. Novel therapeutic uses of alpha-1 antitrypsin: a window to the future. COPD 2012; 9: 5838.
  • 63
    Ross D, Brown T, Harper R et al. Production and characterization of a novel human recombinant alpha-1-antitrypsin in PER.C6 cells. J Biotechnol 2012; 162: 26273.
  • 64
    Yusa K, Rashid ST, Strick-Marchand H et al. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011; 478: 3914.
  • 65
    Mueller C, Flotte TR. Gene-based therapy for alpha-1 antitrypsin deficiency. COPD 2013; 10(Suppl 1): 449.
  • 66
    Kaushal S, Annamali M, Blomenkamp K et al. Rapamycin reduces intrahepatic alpha-1-antitrypsin mutant Z protein polymers and liver injury in a mouse model. Exp Biol Med (Maywood) 2010; 235: 7009.
  • 67
    Hidvegi T, Ewing M, Hale P et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 2010; 329: 22932.
  • 68
    Marciniak SF, Lomas D. Alpha1-Antitrypsin deficiency and autophagy. N Engl J Med 2010; 363: 18634.
  • 69
    Monk R, Graves M, Williams P, Strange C. Inhaled alpha 1-antitrypsin: gauging patient interest in a new treatment. COPD 2013; 10: 4115.
  • 70
    Travis J, Salvesen GS. Human plasma proteinase inhibitors. Annu Rev Biochem 1983; 52: 655709.
  • 71
    Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2002; 165: 14948.
  • 72
    Lewis EC, Shapiro L, Bowers OJ, Dinarello CA. Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc Natl Acad Sci U S A 2005; 102: 121538.
  • 73
    Congote LF. The C-terminal 26-residue peptide of serpin A1 is an inhibitor of HIV-1. Biochem Biophys Res Commun 2006; 343: 61722.
  • 74
    Taggart C, Cervantes-Laurean D, Kim G et al. Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem 2000; 275: 2725865.
  • 75
    Liu Z, Zhou X, Shapiro SD et al. The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell 2000; 102: 64755.
  • 76
    Stoller JK, Brantly M. The challenge of detecting alpha-1 antitrypsin deficiency. COPD 2013; 10(Suppl 1): 2634.
  • 77
    Morris H, Morgan MD, Wood AM et al. ANCA-associated vasculitis is linked to carriage of the Z allele of α₁ antitrypsin and its polymers. Ann Rheum Dis 2011; 70: 18516.
  • 78
    Eden E, Holbrook JT, Brantly ML, Turino GM, Wise RA. Prevalence of alpha-1 antitrypsin deficiency in poorly controlled asthma – results from the ALA-ACRC low-dose theophylline trial. J Asthma 2007; 44: 6058.
  • 79
    Parr DG, Guest PG, Reynolds JH, Dowson LJ, Stockley RA. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2007; 176: 121521.
  • 80
    Strange C. Airway disease in alpha-1 antitrypsin deficiency. COPD 2013; 10(Suppl 1): 6873.
  • 81
    Marciniuk DD, Hernandez P, Balter M et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. Can Respir J 2012; 19: 10916.
  • 82
    Teckman JH. Liver disease in alpha-1 antitrypsin deficiency: current understanding and future therapy. COPD 2013; 10(Suppl 1): 3543.
  • 83
    Hernández Pérez JM, Fumero García S, Alvarez Pío A. Successful α1-antitrypsin replacement therapy in a patient with α1-antitrypsin deficiency and granulomatosis with polyangiitis. Rheumatology (Oxford) 2013; 52: 7557.
  • 84
    Carey EJ, Iyer BN, Nelson DR, Nguyen JH, Krowka MJ. Outcomes in liver transplant recipients for alpha-1 antitrypsin deficiency related cirrhosis. Liver Transpl 2013; 19: 13706.
  • 85
    Banauch GI, Brantly M, Izbicki G et al. Accelerated spirometric decline in New York City firefighters with a1-antitrypsin deficiency. Chest 2010; 138: 111624.
  • 86
    Rodriguez F, de la Roza C, Jardi R, Schaper M, Vidal R, Miravitlles M. Glutathione S-transferase P1 and lung function in patients with alpha 1- antitrypsin deficiency and COPD. Chest 2005; 127: 153743.
  • 87
    Demeo DL, Campbell EJ, Barker AF et al. IL10 polymorphisms are associated with airflow obstruction in severe alpha1-antitrypsin deficiency. Am J Respir Cell Mol Biol 2008; 38: 11420.
  • 88
    Seersholm N, Wilcke JT, Kok-Jensen A, Dirksen A. Risk of hospital admission for obstructive pulmonary disease in alpha(1)-antitrypsin heterozygotes of phenotype PiMZ. Am J Respir Crit Care Med 2000; 161: 814.
  • 89
    Hersh CP, Dahl M, Ly NP, Berkey CS, Nordestgaard BG, Silverman EK. Chronic obstructive pulmonary disease in a1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax 2004; 59: 8439.
  • 90
    Sørheim IC, Bakke P, Gulsvik A et al. α₁-Antitrypsin protease inhibitor MZ heterozygosity is associated with airflow obstruction in two large cohorts. Chest 2010; 138: 112532.
  • 91
    Dahl M, Hersh CP, Ly NP, Berkey CS, Silverman EK, Nordestgaard BG. The protease inhibitor PI*S allele and COPD: a meta-analysis. Eur Respir J 2005; 26: 6776.
  • 92
    Thun GA, Ferrarotti I, Imboden M et al. SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort. PLoS One 2012; 7: e42728.
  • 93
    Rodriguez-Frias F, Miravitlles M, Vidal R, Camos S, Jardi R. Rare alpha-1-antitrypsin variants: are they really so rare? Ther Adv Respir Dis 2012; 6: 7985.
  • 94
    Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ 1997; 75: 397415.
  • 95
    Seersholm N, Wencker M, Banik N et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997; 10: 22603.
  • 96
    The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med 1998; 158: 4959.
  • 97
    Wencker M, Fuhrmann B, Banik N, Konietzko N. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen. Longitudinal follow-up of patients with alpha (1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest 2001; 119: 73744.
  • 98
    Tonelli AR, Rouhani F, Li N, Schreck P, Brantly ML. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Int J Chron Obstruct Pulmon Dis 2009; 4: 44352.
  • 99
    Dirksen A, Dijkman JH, Madsen F et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160(5 Pt 1): 146872.
  • 100
    Dirksen A, Piitulainen E, Parr DG et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33: 134553.
  • 101
    Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD 2009; 6: 17784.
  • 102
    Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev 2010; (7): CD007851.
  • 103
    Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A. Therapeutic efficacy of -1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 2010; 11: 13644.
  • 104
    Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000; 118: 14805.
  • 105
    Barros-Tizón JC, Torres ML, Blanco I, Martínez MT, Investigators of the rEXA study group. Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy. Ther Adv Respir Dis 2012; 6: 6778.
  • 106
    Stoller JK, Fallat R, Schluchter MD et al. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events. Chest 2003; 123: 142534.
  • 107
    Jonigk D, Al-Omari M, Maegel L et al. Anti-inflammatory and immunomodulatory properties of α1-antitrypsin without inhibition of elastase. Proc Natl Acad Sci U S A 2013; 110: 1500712.
  • 108
    Stockley RA, Shaw J, Afford SC, Morrison HM, Burnett D. Effect of alpha-1-proteinase inhibitor on neutrophil chemotaxis. Am J Respir Cell Mol Biol 1990; 2: 16370.
  • 109
    Hubbard RC, Fells G, Gadek J, Pacholok S, Humes J, Crystal RG. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J Clin Invest 1991; 88: 8917.
  • 110
    Bucurenci N, Blake DR, Chidwick K, Winyard PG. Inhibition of neutrophil superoxide production by human plasma alpha 1-antitrypsin. FEBS Lett 1992; 300: 214.
  • 111
    Hansen G, Schuster A, Zubrod C, Wahn V. Alpha 1-proteinase inhibitor abrogates proteolytic and secretagogue activity of cystic fibrosis sputum. Respiration 1995; 62: 11724.
  • 112
    Martin SL, Downey D, Bilton D, Keogan MT, Edgar J, Elborn JS. Safety and efficacy of recombinant alpha1-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 2006; 41: 17783.
  • 113
    Griese M, Latzin P, Kappler M et al. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007; 29: 24050.
  • 114
    Kerem E, Bauer S, Strauss P et al. Safety/efficacy of inhaled human alpha-1 antitrypsin (AAT) in CF: a phase II clinical study. J Cyst Fibr 2009; 8: S25.
  • 115
    He SH, Xie H, Zhang XJ, Wang XJ. Inhibition of histamine release from human mast cells by natural chymase inhibitors. Acta Pharmacol Sin 2004; 25: 8226.
  • 116
    He S, Xie H. Modulation of tryptase and histamine release from human lung mast cells by protease inhibitors. Asian Pac J Allergy Immunol 2004; 22: 20512.
  • 117
    Blanco I, Canto H, Flóres J et al. Long-term augmentation therapy with alpha-1 antitrypsin in an MZ-AAT severe persistent asthma. Monaldi Arch Chest Dis 2008; 69: 17882.
  • 118
    Kalis M, Kumar R, Janciauskiene S, Salehi A, Cilio CM. alpha 1-antitrypsin enhances insulin secretion and prevents cytokine-mediated apoptosis in pancreatic beta-cells. Islets 2010; 2: 1859.
  • 119
    Marcondes AM, Xiang L, Tabellini L et al. Inhibition of IL-32 activation by a-1 anti-trypsin reduces alloreactivity and increases survival in an allogeneic murine marrow transplantation model. Blood 2011; 118: 50319.
  • 120
    Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011; 117: 372032.
  • 121
    Tawara I, Sun Y, Lewis EC et al. Alpha-1 antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 2012; 109: 5649.
  • 122
    Shahaf G, Moser H, Ozeri E, Mizrahi M, Abecassis A, Lewis EC. alpha-1-antitrypsin gene delivery reduces inflammation, increases T-regulatory cell population size and prevents islet allograft rejection. Mol Med 2011; 17: 100011.
  • 123
    Baslund B, Petersen J, Permin H, Wiik A, Wieslander J. Measurements of proteinase 3 and its complexes with alpha 1-proteinase inhibitor and anti-neutrophil cytoplasm antibodies (ANCA) in plasma. J Immunol Methods 1994; 175: 21525.
  • 124
    Blanco I, Béritze N, Argüelles M et al. Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. Clin Rheumatol 2010; 29: 140312.
  • 125
    Schmechel DE, Edwards CL. Fibromyalgia, mood disorders, and intense creative energy: A1AT polymorphisms are not always silent. Neurotoxicology 2012; 33: 145472.
  • 126
    Grimstein C. Combination of alpha-1 antitrypsin and doxycycline suppresses collagen-induced arthritis. J Gene Med 2001; 12: 3544.
  • 127
    Yoshida K, Suzuki Y, Saito A, Fukuda K, Hamanishi C, Munakata H. Aggrecanase-1 (ADAMTS-4) interacts with alpha1-antitrypsin. Biochim Biophys Acta 2005; 1725: 1529.
  • 128
    Grimstein C. Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model. J Transl Med 2011; 9: 21.
  • 129
    Shapiro L, Pott GB, Ralston AH. Alpha-1-antitrypsin inhibits human immunodeficiency virus type-1. FASEB J 2001; 15: 11522.
  • 130
    Münch J, Ständker L, Adermann K et al. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 2007; 129: 26375.
  • 131
    Forssmann WG, The YH, Stoll M et al. Short-term monotherapy in HIV-infected patients with a virus entry inhibitor against the gp41 fusion peptide. Sci Transl Med 2010; 2: 63.
  • 132
    Al-Niaimi F, Lyon C. Severe ulcerative panniculitis caused by alpha 1-antitrypsin deficiency: remission induced and maintained with intravenous alpha 1-antitrypsin. J Am Acad Dermatol 2011; 65: 2279.
  • 133
    Toldo S, Seropian IM, Mezzaroma E et al. Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. J Mol Cell Cardiol 2011; 51: 24451.
  • 134
    Brigham KL, Lane KB, Meyrick B et al. Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy. Hum Gene Ther 2000; 11: 102332.
  • 135
    Brantly ML, Spencer LT, Humphries M et al. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 2006; 17: 117786.
  • 136
    Brantly ML, Chulay JD, Wang L et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A 2009; 2009: 163638. doi: 10.1073/pnas.0904514106. Epub. Erratum. In: Proc Natl Acad Sci U S A 2009 Oct, 13(106), pp. 17606.
  • 137
    Sandhaus RA. Gene therapy meets stem cells. N Engl J Med 2012; 366: 5679.
  • 138
    Niemann H, Kues WA. Application of transgenesis in livestock for agriculture and biomedicine. Anim Reprod Sci 2003; 79: 291317.
  • 139
    Karnaukhova E, Ophir Y, Golding B. Recombinant human alpha-1 proteinase inhibitor: towards therapeutic use. Amino Acids 2006; 30: 31732.
  • 140
    Cantin AM, Woods DE, Cloutier D, Dufour EK, Leduc R. Polyethylene glycol conjugation at Cys232 prolongs the half-life of alpha1 proteinase inhibitor. Am J Respir Cell Mol Biol 2002; 27: 65965.
  • 141
    Sandhaus RA, Stoller JK. Introduction to the 50th anniversary of the description of alpha-1 antitrypsin deficiency. COPD 2013; 10(Suppl 1): 12.
  • 142
    Schünemann HJ, Jaeschke R, Cook DJ et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med 2006; 174: 60514.
  • 143
    Guyatt G, Gutterman D, Baumann M et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American Collof Chest Physicians Task Force. Chest 2006; 129: 17881.